As the lymphotropism of hepatitis C virus (HCV) has already been ascertained, and in the light of the fact that the immune defense system is an organized network composed of functionally interrelated tissues, this study was carried out to verify the possible involvement of spleen in HCV-related chronic hepatitis. In this cross-sectional study we measured spleen longitudinal diameter by ultrasound, beta2-microglobulin serum levels and splenic artery resistivity index (SARI) by Doppler in 51 patients treated with standard combined (Peg-Interferon plus Ribavirin) antiviral therapy. Thirty-three patients (17 females) completed the regimen and were compared to 31 controls (16 females). The mean basal values of spleen longitudinal diameter were higher in patients with chronic hepatitis than in controls, i.e., 116 mm (9.4) versus 102.7 mm (9.3), P = 0.0001. In the same patients a significant trend towards increased spleen longitudinal diameter was found after antiviral therapy, independently of the stage of HCV-related chronic hepatitis. The median values of the beta2-microglobulin concentrations were not significantly higher in the patients with HCV-related chronic hepatitis compared to controls, I.e., 1.3 (0.5 -2.6) versus 1 (0.6 -1.4), P = 0.16, although during the course of therapy they were significantly increased. SARI values of HCV-related chronic hepatitis patients were different from those of controls, but were unvaried compared to values at the end of treatment. Neither spleen measurements nor serum beta2-microglobulin levels were able to predict therapeutic response to antiviral therapy. A stimulation/ expansion of lymphoid tissue was found in patients with HCV-related chronic hepatitis. Such evidence raises the question whether physicians should continue to prescribe antiviral therapy in non-responders and supports the use of a new scheme (SLD plus p2-MG) to diagnose this ongoing, apparently reversible but nevertheless dangerous immunologic process.
defense system is an organized network composed of functionally interrelated lymphoid tissue, in chronic HCV infection one would expect an entanglement and a possible volume increase of organs such as lymph nodes, spleen and liver. Unfortunately, we have very few reports of lymphoid organ involvement in affected patients (4) (5) . Although in chronic HCV infection the reticulo-endothelial system of the spleen plays a major role in removing the immune complexes (6) , this organ is considered as scarcely involved, at least in non-advanced liver disease (7) . Equally, the difference in liver volume between patients with chronic HCV hepatitis and healthy subjects is not significant (8) . Interestingly, interferon (IFN)-alpha therapy seems to enhance the colloidal uptake function of Kupffer cells (9) .
Imbalance between Th1 and Th2 lineages is thought to playa key role in the persistence ofHCV infection. The differentiation of naive CD4+ T cells into Thl or Th2 lineages is significantly influenced by dendritic cells (DCs, 10). Spleen DCs express very high levels ofmajor histocompatibility complex (MHC) class I and class II antigens (11) . DCs from people with chronic HCV infection have impaired capacity to stimulate T cells as a consequence of altered expression of MHC (12) . Interestingly, the function of DCs seems to be negatively affected by beta2-microglobulin (P2-MG) (13) . High serum levels of p2-MG have been found in HCV-related chronic hepatitis (14) .
IFN influences the synthesis ofp2-MG, causing it to rise (15) and playing a significant role in regulating the differentiation into Thl or Th2 lineages (16) . The DCs that differentiate from monocytes in the presence of high levels of p2-MG have an increased concentration of the Th2-derived cytokine IL-6 (13) . Indeed, the contribution of the spleen to whole-body IL-6 production is currently clear (17) . Finally, high serum levels ofIL-6 have been detected in the course of HCV hepatitis and have been correlated to both liver function impairment and hepatic fibrosis (18) .
In a previous study, performed with a threedimensional reconstruction of Computed Tomography (CT) images of the spleen, a good correlation was found between linear spleen measurement on UltraSound (US) and spleen volume (19) (20) . Furthermore, various reports have shown that spleen volume is a stable and easily assessable index (21) . On the other hand, Splenic Artery Resistivity Index (SARI): i) has been considered a good parameter to help diagnose (22) hemodynamic abnormalities (enhanced inflow at the arterial level), such as those associated with portal hypertension; ii) has already proven to be a further non-invasive tool in separating non-alcoholic fatty liver disease patients from healthy subjects (23); iii) has not been as criticized as other Doppler parameters (24) .
According to the aforementioned evidence and stressing the concept that HCV infection persists for decades due to cellular immune response escape, it is reductive to consider that the spleen does not play any role. To help clarify this somehow controversial issue, a study was carried out in a population ofnoncirrhotic HCV-infected patients and a comparable group of healthy subjects, evaluating spleen volume as a possible index of lymphoid tissue expansion. Furthermore, we sought to determine the extent to which the levels of p2-MG, detected in any chronic infectious processes involving CDs, including HCV, were comparable to spleen size. Finally, these measures were evaluated in a prospective fashion after intervention with combined antiviral therapy, in order to assess whether a subsequent stimulation! expansion ofthe immune lymphatic system impacted on this organ.
MATERIALS AND METHODS

Chronic hepatitis C patients
Sixty-eight patients with elevated values of serum alanine aminotransferase (ALT) for at least six months and detectable serum HCY-RNA were diagnosed as having HCY-related chronic hepatitis. All of them had genotype 1. Fifty-five patients (28 females) underwent liver biopsy, before starting antiviral treatment. Histological features were evaluated using the Ishak scoring system for inflammation and fibrosis (25) . In brief, inflammation was scored using four parameters (periportal or periseptal interface hepatitis, confluent necrosis, focal lytic necrosis and portal inflammation) to obtain a maximum Histological Activity Score of 18; severity of fibrosis scores ranged between 0 and 6. Tissue specimens from selected patients were considered adequate for evaluation when at least four portal (or septal) areas were available for review and if their length was greater than 1.5 em. A standard EMEAapproved dose regimen of PEG IFN alpha-2b (1.5 meg! kg weekly) and ribavirin (RBV, 1000 mg if the patient's weight was 75 kg and 1200 mg daily if it was> 75 kg) was initiated in 51 patients. Dose reductions and the use of growth factors were allowed for the management of anemia, neutropenia and thrombocytopenia. Filgrastim, 300 meg weekly, was given to four patients because their absolute neutrophil count dropped below 750/f.lP. In one patient, whose neutrophil count been long below these limits, the PEG IFN regimen was decreased. The PEG IFN dose was also decreased in two patients whose platelet counts were below 80000/f.lP. Erythropoietin 10,000 U was administrated subcutaneously once weekly in seven patients because their hemoglobin had dropped 2 g compared to pre-treatment values, or whenever they were below 10 g/dL. In five out ofseven patients, the RBV dose was reduced by 200-400 mg because of the persisting condition of anemia, and was discontinued whenever hemoglobin values were < 8 g/dL. In six patients, Peg! RBV doses were either reduced or their administration discontinued due to disabling fatigue or severe depression not responsive to anti-depressant therapy. The efficacy endpoints were as follows: Virological Response at the end of therapy (EnTVR) and Sustained Virological Response (SVR) defined as undetectable serum HCV-RNA soon after the discontinuation of anti-viral treatment and after 6 months. The combined antiviral therapy lasted 48-52 weeks. Treatment was interrupted in nine patients who did not show early virologic response (EVR) at week 12 of therapy (defined by negative HCV-RNA or > 2 log drop in HCV-RNA from pretreatment viral load).
Exclusion criteria
Patients were excluded if they met at least one of the following criteria: presence of co-infection with HBV or HIV; active drug addiction; alcohol consumption 201 40 g/day for females and males, respectively; previous treatment for HCV infection; imaging evidence of hepatocellular carcinoma; presence of cryoglobulinemia.
Flow ofstudy population
Patients who discontinued therapy prematurely due to side effects or lack of EVR or who had been treated with growth factor(s) were not considered suitable for the study, due to their potential confounding impact on spleen (an intention-to-treat analysis was not applied, as the main aim was not to weigh the antiviral therapy efficacy). A study addressing this last aspect is in progress. The final groups of this cross-sectional study comprised 33 patients (17 females) with HCV-related chronic hepatitis and 31 individuals (16 females) who acted as controls.
Viral evaluation
Serum HCV-RNA was determined qualitatively by a commercial RT-PCR test (Amplicor HCV; Roche, Italy) and quantified using an Amplicor HCV Monitor (version 2.0; Roche); the lower detection limit was 50 IU/mL. The amplified product was analyzed using a reverse dot blot assay (Innol.ipa", Innogenetics, Zwijnaarde, Belgium) according to the manufacturer's instructions, to determine HCV genotypes.
Immunological evaluation
Serum~2-MG levels were determined by an ELISA test (BioCheck, CA USA) with a reported mean of normal values equal to 1.42 +1-0.508 mcg!mL and a range obtained by mean +1-2 SD of 0.4-2.8 mcg/mL. The minimum detectable concentration of the~2-MG ELISA assay as measured by 2 SD from the mean of a zero standard was estimated to be at least 0.1 ug/ml, The coefficient of variation (%) of intraassay and interassay was 6.8 and 5.01, respectively.
Imaging study
Spleen Longitudinal Diameter (SLD) was performed by postero-lateral scanning at US. The Maximum Length (ML, the optically greatest overall longitudinal dimension obtained from one of the two poles) and the CranioCaudal Length (CCL, the optically maximal transversal dimension intercepting one of the two poles) were measured; the resulting values were then averaged, since the two measurements do not always coincide. SLD (ML + CCL 12) was also measured in controls, where the upper limit of the 90% reference interval was detected using a parametric percentile method.
SARI was calculated with the following formula: RI = peak systolic velocity -end systolic velocity 1 peak systolic velocity. The probe was positioned below the left costal arch or in the left costal spaces. Color Doppler allowed identification of the main branches of the splenic artery. Anti-hypertensive drugs were withdrawn at least three days before the test.
Statistics
Normally distributed variables (Shapiro-Wilk normality test) such as Body Mass Index (P = 0.3), SLD, pre-treatment values (P = 0.56), values after six months (P =0.19),12 months (P= 0.13), and 18 months (P=0.17) of treatment as well as~2-MG after six months (P = 0.35), 12 months (P = 0.08), 18 months (P = 0.48) of treatment were expressed as mean (SD). Those not normally distributed such as ALT (P = 0.002), pre-treatment~2-MG (P = 0.001), pre-treatment and after 12 month-treatment SARI (P = 0.001 and 0.003, respectively) as well as ordinals, i.e., histology scores, were expressed as median (range). The chi square test was evaluated to analyze frequencies.
The Wilks's Lambda (W-L) one-way analysis of variance with repeated measures was adopted to study the differences of findings within the study period, and precisely: i) between six, 12 and six months after therapy (18 months) data, utilizing pre-therapy (time 0) values alone or both time 0 and stage score as Covariates (ANCOVA); ii) between pre-therapy, six and 12 months data, selecting 18 months values as Covariate.
The unpaired t test and the Mann-Whitney test were used to compare variables normally, or not normally distributed, such as SLD and~2-MG or SARI, in HCV and control groups, respectively. The paired t test was employed when comparing the SLD and~2-MG value before and after antiviral therapy. The paired Wilcoxon test was used to compare basal and post-treatment SARI values.
To predict the response to antiviral therapy the logistic regression (Enter Method, Odds ratio plus CI) was employed utilizing as independent variables US values for SLD and serum~2-MG concentrations at different time. To assess the independent effect of SLD values on the prediction of a quantitative variable, i.e., 2-MG, or on stage scores, linear regression analysis was used and the estimate was given reporting the beta. The association between pre-treatment ALT activity and~2 MG levels was evaluated using the Spearman's rho. The concordance correlation coefficient (Pc')' which measures precision and accuracy, was adopted to evaluate the degree of pair observations at US. Statistical analysis was performed operating on Systat 12 and MedCalc Version 10.4 software packages.
This study was conducted according to the Guidelines ofthe International Conference on Harmonization for Good Clinical Practice, in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).
RESULTS
The population characteristics are shown in Table  I . SLD values were significantly higher in patients with chronic HCV hepatitis than in healthy subjects, i.e., 116.8 mm (9.4) vs 102.7 mm (9.3) (P < 0.001, unpaired t test, Fig. 1 ). Specifically, only three out of 31 Controls (9.7%) had values in the upper range of normality, approaching 115 mm as the upper limit of our reference interval of SLD. In more than onethird of HCV patients (13/33, 39.4%) SLD values ranged between 120 and 136 mm (far above their mean value and the reference upper limit). The number of HCV patients and healthy subjects with SLD values below 107 mm, i.e., the lower 95% CI limit, was 4/33 (12%) and 24/31 (77%), respectively (chi square = 5.9, P = 0.01). SLD values were not predicted by staging scores of chronic HCV hepatitis (beta 0.175, P = 0.437).
SLD measurements slowly but constantly increased when detected during the course of the combined antiviral therapy (W-L = 0.69, P = 0.004, ANCOVA) and declined at the 18 th month (W-L = 0.81, P = 0.04, ANCOVA), six months after the end of therapy, with a mean value not much dissimilar from that found before starting therapy (paired t test, P = 0.085, Fig. 2) .
When controlling for the extent, i.e., stage, of fibrosis, the significance obtained analyzing the data during therapy did not change (W-L = 0.59, P = 0.009, ANCOVA). Spleen size never predicted the response to antiviral therapy (basal SLD = OR 1.07, CI 0.9-1.3, SLD at six months = OR 1.03, CI 0.86 -1.24, SLD at 12 months OR = 0.95, CI 0.77 -1.16, SLD at 18 months OR = 0.95, CI 0.8 -1.1).
The basal median value of the p2-MG concentrations of the patients with chronic HCV hepatitis (n = 33) was not significantly enhanced compared to that of Controls (n = 18), i.e., 1.3 (0.5 -2.6) vs 1 (0.6 -1.4), P = 0.16, Mann-Withney test. A pattern quite similar to that of SLD was followed by p2-MG during the course of therapy (W-L = 0.77, P = 0.02, ANCOVA) and at the 18 th month (W-L = 0.09, P < 0.001, ANCOVA). Higher SLD values at the end of antiviral therapy quite accurately predicted lower basal values ofp2-MG (beta -0.41, P = 0.017, Fig. 3) . At all the times considered, p2-MG concentrations were unable to predict the response to therapy. A significant association was evidenced between pre-treatment ALT activity and p2-MG levels (rho = 0.29, P = 0.039).
Basal SARI values in patients with chronic HCV hepatitis highly differed from those of controls, i.e., median 0.57 (0.54 -0.59) vs 0.55 (0.53 -58), (P < 0.001, Mann-Withney test), although they did not differ from the values at the end of therapy 0.57 (0.54 -0.59) (P = 0.06, paired Wilcoxon test).
As to the accuracy of US, the averaged intraobserver error of the linear (SLD) ultrasound measurements was extremely reduced, e.g., < 6%; regarding inter-observer error, P, ranked high, (Pearson p = 0.93), whereas for SARI, Pc ranked sufficiently higher (Pearson p = 0.87).
DISCUSSION
The key findings regarding our patients with 
I I
Hepatitis C Virus (HCV), Spleen Longitudinal Diameter (SLD), Body Mass Index (BMI), Beta2-microglobulin (fJ2-MG), Splenic Artery Resistivity Index (SARI), ALanine aminoTransferase (ALT), not determined (nd).
chronic HCV hepatitis are, in brief: i) significantly enhanced ultrasonographic evidence of SLD; ii) elevated serum~2-MG concentrations only during therapy; iii) increased spleen volume at the end of antiviral course, accurately predicted by the low basal levels of~2.;.MG; iv) SARI Values at cessation of therapy not significantly' increased compared to basal values; v) response to treatment unrelated tõ 2-MG and SLD values. Our data somehow disagree with the body of currently available knowledge, providing evidence for the hypothesis that germinative centres and red pulp of the spleen could be involved in chronic HCV infection. Subsequently, we failed to find increased 2-MG values in our patients with chronic HCV hepatitis, at least in basal conditions. Based on these results, we observe that not even the increase in spleen volume after antiviral therapy supports the previous findings (7). In fact, IFN acts through activation and maturation of DCs, leading to MHC up-regulation and modulating T lymphocyte responses.through the promotion ofThl differentiation (26) .
As to the possible discrepancies in' our findings, such as why~2-MG increase does not parallel SLD boost, we hypothesize that the failure of f32-MG to keep up with SLD is explained by the fact that high basal values ofthis cytokine negatively influence the expansion of lymphatic tissue. Another divergence could be represented by the apparent separation of the two organs, i.e., spleen and liver. The fact that the peripheral immune response,' as mediated by the spleen, apparently affected a distant organ is definitely proven by recent research focusing on neuro-degeneration after stroke (27) . Equally, spleen size appears to be involved in the metabolic syndrome-related non-alcoholic steatohepatitis, characterized by a systemic low-grade chronic inflammation (23) . During HCV infection the stimulation of CD4 T-lymphocytes is induced and, although the highest number is present at the site ofthe on-going inflammatory process (28) , the production is of splenic origin. Still, to what extension does portal hypertension determine the increased spleen volume? It is believed that passive venous congestion is the major cause of splenomegaly in chronic liver disease. However, there is a poor correlation between portal venous pressure and spleen size (29) and only SARI measurements, as reported in our study, cast many doubts on the possible presence of portal hypertension in patients with chronic HCV hepatitis. Furthermore, the increase in SLD during the course of therapy was not different even when adjusted for the entity of fibrosis, nor were SLD basal values predicted by the staging scores. Aside from its established immunologic and hematologic functions, the spleen plays an important role in vascular regulation. In essence, this occurs through changes in intrasplenic microvascular tone, as well as through splenic neurohormonal modulation of the renal and mesenteric vascular beds (30) . Therefore, the increase in spleen volume could be the cause rather than the effect of portal hypertension. Coming back to the enhanced spleen size in our patients, and taking into consideration the reliability of this core parameter in the US diagnosis of lymphomatous involvement of the spleen (31) , an obvious consideration is whether the increased volume, indicating expansion of lymphatic organ, could be interpreted as benign or possibly dangerous, foreseeing a malignant development. Unfortunately, this question remains unanswered, but it is noteworthy to emphasize that a causative role of HCV in lymphoproliferative disorders has been suggested by several reports. What about the failure to evaluate lymphocyte populations in the present study and the bias towards a missed suggestion to use flow cytometry for patient follow-up? This tool represents an "instant snapshot" and does not reflect a long-lasting assessment. Besides, the testing is complex, not easily standardized, and often provides descriptive, qualitative findings that supplement rather than supplant other diagnostic procedures (32) .
The clinical implications summarized in a straightforward and circumspect manner of the work are that our data reinforce: i) the need to stop the available antiviral therapy at the "earliest possible time" in the non-responder patients to avoid a prolonged stimulation of lymphoid tissue, or the worsening of an exaggerated immune response by HCV (33) ; ii) the possibility to come up with a new scheme (SLD plus~2-MG) to diagnose this ongoing potentially dangerous, albeit apparently reversible, immunologic process. 
